Tanggene
TangGene develops first-in-class in vivo, tissue-specific CD8+ Treg cell therapy for autoimmune diseases. The company utilizes a proprietary nanoparticle platform to reprogram dendritic cells, stimulating the expansion of CD8+ Tregs. This approach aims to restore immune tolerance and provide lasting remission for patients with conditions like multiple sclerosis.
Traction –/10
HQ unknown
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- TangGene develops first-in-class in vivo, tissue-specific CD8+ Treg cell therapy for autoimmune diseases. The company utilizes a proprietary nanoparticle platform to reprogram dendritic cells, stimulating the expansion of CD8+ Tregs. This approach aims to restore immune tolerance and provide lasting remission for patients with conditions like multiple sclerosis.